Bayer May Not Launch In Innovation-Unfriendly European Markets
Concerns Growing Over Current Environment
The attractiveness of investing in R&D and launching new products in Europe is wearing off, especially when compared with the US marketplace, Bayer pharma head Stefan Oelrich tells Scrip.
